CheckMate914

EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse

CheckMate 914: Nivo/Ipi in RCC - Slideset Download - ESMO Congress Paris

Summary of Research: Adjuvant Nivolumab Plus Ipilimumab Versus Placebo for Localized Renal Cell Carcinoma After Nephrectomy (CheckMate 914): A Double-Blind, Randomized, Phase 3 Trial

Ziad Bakouny, MD, MSc on X: Dr. @motzermd with an important presentation of #CHECKMATE914 Part A subgroup analyses. @ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of

Enrique Grande on LinkedIn: #immunotherapy

New Perioperative Strategies Emerge for High-Risk, Resectable RCC

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Fine-Tuning the Wave of Innovation in RCC

Optimal Choice of Adjuvant Treatment for Renal Cell Carcinoma Followin

CheckMate 914: Nivolumabe adjuvante mais ipilimumabe no tratamento do carcinoma de células renais localizado com alto risco de recidiva - Oncologia Brasil

Adjuvant Therapy in Renal Cell Carcinoma: Are We Ready for Prime Time? - IOS Press

Frontiers Adjuvant therapy for renal cell carcinoma, finally a new standard?

Nivolumab Alone, Plus Ipilimumab Being Tested in Early-Stage, High-Risk RCC

EAU 2019: Post-Nephrectomy Adjuvant Therapy for Localized Renal Cell Carcinoma: CheckMate 914 Study of Nivolumab + Ipilimumab in Patients at High Risk of Relapse

Et de 3 ! CheckMate 914 : encore un essai négatif en adjuvant pour le rein